Home
overview

SMi’s 5th Annual Conference
3D Cell Culture
February 10-11, 2021 | London, Copthorne Tara, United Kingdom
-------------------------------------------------------------------------
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027, researchers globally are realising the growing potential of in vitro applications for drug discovery, predictivity and validation, safety and toxicity.

Rising demand for tissue engineering for the treatment of chronic diseases is a key driver of this research and new technologies in the form of organ-on-chip, microphysiological systems and 3D bioprinting are all significant emerging areas of the field.

Join us in February 2021, as SMi’s 5th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies and the leading biotech companies in the field to discuss the challenges and drivers of the industry, through case studies of the latest innovations in 3D Cell Culture models, real world examples of applications of new technologies and insights into 3D imaging and high throughput screening to give you a comprehensive this fast growing industry.
 

Highlights for 2021
• DISCOVER the cutting-edge technology that is changing the face of pharmaceutical drug development
• EXPLORE the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives
• INSIGHT into the capacity for Microphysiological Systems and Organ-on-a-Chip technology to mimic cellular microenvironments in vitro
• DISCUSS current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery
• ASSESS the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops
 
 

 

Key Job Titles include Head of, Director, Manager of...

  • Complex in vitro models
  • Cell and molecular science
  • Disease models
  • Cell technology
  • Microphysiological systems
  • Microfluidics
  • Toxicology
  • Stem Cell Sciences
  • Tissue Engineering
  • High throughput screening
  • 3D Imaging

 

University College London, GSK; Aixtron Ltd; AstraZeneca; BioLamina AB; Boehringer Ingelheim RCV GmbH & Co KG; Cellbox Solutions GmbH; Cellink; CN Bio Innovations Limited; DMPK; Durham University; Engitix Ltd; Enplas; EPO; European Patent Office; FabRx Ltd; Gadeta B.V.; Genentech; GlaxoSmithKline; GSK; Hitachi High-Technologies Corporation; Institute Pasteur; Lund University; Manchester BIOGEL; Medicines Discovery Catapult; Merck; Merck Healthcare KGaA; Merck KGaA; MHRA; Mimetas; MRC Harwell Institute; MRS Mammalian Genetics; NC3Rs; Newcastle University; Novartis Pharma AG; Novo Nordisk A/S; OpenCell ; Promega UK Ltd; Rousselot - gelatin; Sanofi Pasteur; Sartorius; TreeFrog Therapeutics; Unilever Research Laboratory; University College London; University Of Strathclyde; Viscofan S.A;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

Stefan Przyborski

Stefan Przyborski, Professor of Cell Technology, Durham University
View Bio

9:10 Designing 3D peptide-based scaffolds for cell culture application: From design to commercialisation

Alberto Saiani

Alberto Saiani, Professir of Molecular Materials, University Of Manchester
View Bio

• Supramolecular assembly as a tool for material design
• Peptide’s potential as structural and functional building blocks for 3D scaffold building
• Materials-cell interactions: from adhesion to remodelling
• Commercialisation challenges in the 3D scaffold field
 

9:50 Modelling diseases in Organoids

• New insights into disease mechanisms
• The latest developments in drug treatment strategies

Robert Vries

Robert Vries, CEO, Hubrecht Organoid Technology
View Bio

10:30 Morning Coffee

11:00 A model for assessing repeated-dose drug toxicity

Stephen J. Fey

Stephen J. Fey, Founder and Chief Research Officer, Celvivo

• Response to- and recovery from- treatment
• Metabolic reprogramming
• Clinostat cultures for keeping cells in a dynamic equilibrium
 

11:40 Use of advanced cell technologies to construct in vitro models of human tissues

Stefan Przyborski

Stefan Przyborski, Professor of Cell Technology, Durham University
View Bio

• Impact and importance of 3D cell culture and advanced cell technologies
• Beyond 3D cell culture as a technique, applications to building human tissues in vitro
• Generating highly specialized models of human tissues – examples of skin and intestinal mucosa
• New innovations and developments to further enhance bioengineered tissue technology
 

12:20 Networking Lunch

13:20 Advancing Regulatory Science through innovation - in vitro Microphysiological Systems

Suzanne Fitzpatrick

Suzanne Fitzpatrick, Senior Science Advisor for Toxicology, FDA
View Bio

• Regulation keeping pace with advances in basic and applied science and technology
• Identifying modern toxicological tools that will improve preclinical safety predictions for regulatory use
• Developing in vitro microphysiological systems to bring innovative new technologies into the regulatory paradigm
• Collaborating to develop organs on a chip to screen for safe and effective products with more efficiency than current methods

14:00 Development and adoption of microphysiological systems for drug safety assessment

Rhiannon David

Rhiannon David, Associate Principal Scientist, AstraZeneca
View Bio

• Outline the context of use of microphysiological systems (MPS) to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models
• Highlight examples of data generated from these systems that demonstrate the utility of MPS for safety assessment
• Current challenges to the adoption and/or development of MPS in the pharmaceutical industry
 

14:40 Afternoon Tea

15:10 Micro-physiological systems (MPS): Where are we now?

Pedro Pinto

Pedro Pinto, Laboratory Manager, University of Greifswald – Medical Centre
View Bio

• MPS in research and development
• Advantage of MPS models
• Practical applications of MPS
 

15:50 Importance of going 3D: Benefits of capturing the physiology accurately to increase clinical translation

Pelin Candarlioglu

Pelin Candarlioglu, Investigator - Bioengineer/Cell Biologist, GSK
View Bio

• The need to mimic the tissue architecture correctly to be able to maintain relevant function that requires 3D and beyond
• Incorporating new OoC models in immuno-oncology workflow: Key aspects to consider
• Selected examples of OoC for Efficacy Models in immuno-oncology
• Future roadmap in the OoC strategy for oncology
 

16:30 Chair’s Closing Remarks and Close of Day One

Stefan Przyborski

Stefan Przyborski, Professor of Cell Technology, Durham University
View Bio

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Stefan Przyborski

Stefan Przyborski, Professor of Cell Technology, Durham University
View Bio

9:10 Using 3D cell culture for high throughput drug discovery

Sakshi Garg

Sakshi Garg, Lab Head, Merck Group

• Importance of 3D cell culture for compound testing
• Mimicking the tumour microenvironment
• Adapting the HTS system to handle 3D spheroids
• Multiplexing analysis from spheroids
 

9:50 Assessing the applicability of 3D human liver spheroids in early safety screening

Freddy Van Goethem

Freddy Van Goethem, Scientific Director, Fellow, Johnson & Johnson; Janssen Pharmaceutical
View Bio

• Cytotoxicity profiling
• Transcriptomic profiling
• Proof of concept study

10:30 Morning Coffee

11:00 2D vs. 3D in drug discovery: A High Content Screening perspective

Thierry Dorval

Thierry Dorval, Data Scientist Lab Group Leader, Servier
View Bio

• High Content Screening & Imaging
• 3D spheroids
• Multivariate data analysis
 

11:40 Applying 3D cell cultures to high-throughput drug discovery

Alejandro Amador

Alejandro Amador, Director, Cellular Assays and Technologies, Incyte
View Bio

• Accelerating drug target identification and validation through clinically relevant in vitro models
• Utilising wide array screening and human-relevant organoids for oncological drug discovery
• Interrogating gene function to identify new oncology combination therapies
• Facilitating industry implementation and qualification of microphysiological systems
 

12:20 Networking Lunch

13:20 Addressing the clinical translatability of Microphysiological Systems for drug assessment and development

  • Assessing the relevance of 3D cell models to humans and animals
  • Mimicking the natural microenvironments and architectures of functioning tissues
  • Successfully predicting preclinical toxicity and potential metabolic liability
  • Outlining the regulatory relevance of MPS from the clinical stage onwards
     
  • Pelin Candarlioglu

    Pelin Candarlioglu, Investigator - Bioengineer/Cell Biologist, GSK
    View Bio

    Suzanne Fitzpatrick

    Suzanne Fitzpatrick, Senior Science Advisor for Toxicology, FDA
    View Bio

    Pedro Pinto

    Pedro Pinto, Laboratory Manager, University of Greifswald – Medical Centre
    View Bio

    Rhiannon David

    Rhiannon David, Associate Principal Scientist, AstraZeneca
    View Bio

    14:00 From Bedside to Bench – Translation of Clinical Protocols into 3D Culture

    Andreas Thomsen

    Andreas Thomsen, Senior Physician, University of Frieberg
    View Bio

    • A look at clinical oncology from a laboratory perspective
    • Approaches to mimic the clinical situation in vivo
    • Assessment of treatment response in 3D long term cell cultures
     

    14:40 Afternoon Tea

    15:10 An immunological tumour infiltration platform for target discovery

    Julian Bahr

    Julian Bahr, Postdoctoral Fellow, AstraZeneca
    View Bio

    • Developing a novel three-dimensional spheroid-splenocyte co-culture system
    • Recapitulating in vivo immune infiltration phenotypes by four-color imaging of the co-culture
    • Efficient CRISPR-mediated gene KO in the co-culture system
    • Evaluation of a CRISPR KO screen for immunological tumour infiltration targets using high-content imaging
     

    15:50 Growing human bone in a bone-on-chip

    Elisa Budyn

    Elisa Budyn, Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay

    • New bone formation by human mesenchymal stem cells (MSCs) in vitro is a challenge. A bone-on-chip based on human decellularised native bone is proposed as a physiologically relevant 3D environment for human bone cell recellularisation
    • The bone-on-chip successfully led to stem cell derived osteocytes (SCDOs) from either primary adult MSCs or foetal osteoblast progenitors. FTIR and histo-chemistry showed the cells produced a mineralised collagen matrix mimicking the chemical heterogeneity of native bone. Confocal microscopy showed the matrix’s layered microstructure.
    • Fluorescent microscopy showed the cells adapted their calcium response to the expected in vivo mechanical stimulations at different stages of differentiation. The new bone displayed a flexural modulus ranging from 25 to 100% of the decellularised bone stiffness between 109 and 126 days.

    • The bone-on-chip offers promising opportunities for organ culture up to over 26 months for bone formation study, cell diagnosis or cell reprogramming...
     

    16:30 Biofabrication strategies for next-generation 3D models of human skin

    John Connelly

    John Connelly, Reader in Bioengineering, Queen Mary University of London

    • The application of a novel high-content screening platform to investigate cell migration and wound healing
    • The development of bioinks for 3D bioprinting of human skin equivalents
    • Biofabrication strategies for the development of vascularised and immune-response skin models
     

    17:10 Chair’s Closing Remarks and Close of Day Two

    Stefan Przyborski

    Stefan Przyborski, Professor of Cell Technology, Durham University
    View Bio

    +

    FEATURED SPEAKERS

    Alberto Saiani

    Alberto Saiani

    Professir of Molecular Materials, University Of Manchester
    Alejandro Amador

    Alejandro Amador

    Director, Cellular Assays and Technologies, Incyte
    Andreas Thomsen

    Andreas Thomsen

    Senior Physician, University of Frieberg
    Julian Bahr

    Julian Bahr

    Postdoctoral Fellow, AstraZeneca
    Pedro Pinto

    Pedro Pinto

    Laboratory Manager, University of Greifswald – Medical Centre
    Pelin Candarlioglu

    Pelin Candarlioglu

    Investigator - Bioengineer/Cell Biologist, GSK
    Robert Vries

    Robert Vries

    CEO, Hubrecht Organoid Technology
    Sakshi Garg

    Sakshi Garg

    Lab Head, Merck Group
    Stefan Przyborski

    Stefan Przyborski

    Professor of Cell Technology, Durham University
    Stephen J. Fey

    Stephen J. Fey

    Founder and Chief Research Officer, Celvivo
    Suzanne Fitzpatrick

    Suzanne Fitzpatrick

    Senior Science Advisor for Toxicology, FDA
    Thierry Dorval

    Thierry Dorval

    Data Scientist Lab Group Leader, Servier

    Alberto Saiani

    Professir of Molecular Materials, University Of Manchester
    Alberto Saiani

    Alberto Saiani is currently Professor of Molecular Materials at the University of Manchester. He graduated PhD in Polymer Physics from the University Louis Pasteur, Strasbourg, France. Following his PhD he held several post-doctoral positions in Japan, UK and Belgium before joining in 2002 the University of Manchester where he established the Polymers & Peptides Research Group (polymersandpeptides.co.uk). His work includes fundamental, industrial, and translational research and spans a wide area of experimental polymer and biopolymer science. In 2014 he co-founded a start-up company, Manchester BIOGEL (manchesterbiogel.com), which develops and commercialises advanced gel-based combination products for the life science and biomedical sector.

    Alejandro Amador

    Director, Cellular Assays and Technologies, Incyte
    Alejandro Amador

    Alejandro Amador is an experienced PhD leader. He leads the Cellular Assays and Technologies (CAT) group at Incyte, a multidisciplinary team of 8 scientists, including cell and molecular biologists. His team is focused on accelerating the identification of high value hits using high-throughput automation and human relevant cell based models. In addition, his team is responsible to deliver on new technologies at Incyte.
    Prior to working Incyte, he led the High Throughput Biology (HTB) group at GSK. His team built a fully automated robotic platform to perform high throughput screening and CRISPR/Cas9-based genome editing strategy for functional screening.
     

    Andreas Thomsen

    Senior Physician, University of Frieberg
    Andreas Thomsen

    EDUCATION: Medical studies (1992-1999)
    Eppendorf University Hospital, Hamburg, Germany
    EMPLOYMENT:
    University Medical Center Freiburg, Dept. of Radiation Oncology currently, since 06-2008 Senior physician in clinical radiation oncology
    CellGenix Technologie Transfer GmbH, Freiburg 04-2005 - 05-2008 Head of production chondrocytes, head of quality control hematopoietic stem cells
    University Medical Center Freiburg, Lab of maxillofacial surgery 10-2003 - 03-2004 Research fellow, tissue engineering of craniofacial bone tissue
    BioTissue Technologies AG, Freiburg 02-2001 - 09-2003 Research and Development, autologous maxillofacial tissues
    University Medical Center Hamburg, Institute of Anatomy 10-1999 - 01-2001 Research fellow, teaching of gross and microscopic anatomy
    PROFESSIONAL MEMBERSHIPS:
    European Society of Hyperthermic Oncology (ESHO)
    Society of Thermal Medicine (STM)
    German Society of Radiation Oncology (DEGRO)

    Elisa Budyn

    Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
    Elisa Budyn

    Freddy Van Goethem

    Scientific Director, Fellow, Johnson & Johnson; Janssen Pharmaceutical
    Freddy Van Goethem

    Freddy obtained his Ph.D. degree in Science at the Free University of Brussels (Belgium) in 1995. After his post-doc, he joined Janssen (Belgium) as a Study Director for Genotoxicity testing and In Vitro Alternatives for topical toxicity. From 2003 to 2009, Freddy was the chairman of the Belgian Environmental Mutagen Society.
    During his career, he was responsible for the identification and validation of new in vitro test systems to assess the genotoxic and cytotoxic potential of compounds in early drug development. Today, he’s heading the Cell Health Assessment group responsible for early safety screening and evaluation of advanced test systems.
     

    John Connelly

    Reader in Bioengineering, Queen Mary University of London
    John Connelly

    Julian Bahr

    Postdoctoral Fellow, AstraZeneca
    Julian Bahr

    Julian Bahr has been a Postdoctoral Fellow at AstraZeneca since 2018, where he is developing new 3D models for immunotherapy target discovery. His scientific training began at the National Institutes of Health under Dr. Susan Bates studying the mechanisms of HDAC and MAPK pathway inhibitors on KRAS mutant cancers. He went on to research macrophage-mediated basement membrane remodeling with Dr. Stephen Weiss for his Ph. D. work at the University of Michigan. Julian is passionate about elevating Ph.D. and Postdoctoral science and has continuously held leadership positions in the research organizations he has been a part of.

    Pedro Pinto

    Laboratory Manager, University of Greifswald – Medical Centre
    Pedro Pinto

    My research is focused on investigating renal function in vitro, namely the development of assays to study the activity and regulation of renal drug transport mechanisms, using advanced cell models . In 2017 I was award my PhD from the University of Utrecht, and shortly after joined AstraZeneca. During my time with AZ I was involved in establishing the use of micro-physiological system (MPS), mimicking human renal physiology, to study drug transport through the renal epithelium. Recently I moved to the University of Greifswald, Germany, where I am continuing my research dedicated to renal function and expanding to other areas including kidney and urological cancers.

    Pelin Candarlioglu

    Investigator - Bioengineer/Cell Biologist, GSK
    Pelin Candarlioglu

    Pelin is a tissue engineer by training having received her PhD in the field from Imperial College London. Soon after, oncology presented itself as a more interesting area to move into which led to the PostDoc position about circulating tumour cells at the UCL. Since then she has been working on various aspects of oncology continuously. Her introduction to Organ On Chip was when she was running a Cell Biology/Microfluidics lab in Cambridge at Enplas Corporation where she was developing a unique tumour-on-chip design specifically for immuno-oncology. Her current role in GSK is to bring OoC expertise for both epithelial/barrier models as well as oncology. She is leading many external and internal projects to develop, characterise and validate different OoC models for safety, efficacy and PK/PD applications.

    Rhiannon David

    Associate Principal Scientist, AstraZeneca
    Rhiannon David

    Dr Rhiannon David is Scientific Lead for Microphysiological Systems (MPS) in Clinical Pharmacology and Safety Sciences at AstraZeneca, Cambridge, UK. Rhiannon received her PhD from the University of Birmingham in 2009 following which she joined the Department of Medicine at Imperial College, London, where she spent 5 years as a postdoctoral scientist, undertaking research into the genotoxicity of mixtures. During this time, Rhiannon developed an interest in novel techniques that would improve the in vivo relevance of in vitro assays. Rhiannon joined AstraZeneca in 2015 where she has led the development of a bone marrow MPS for improved pre-clinical safety assessment as well as taking an active interest in the development of MPS more broadly for advancing safety assessment.

    Robert Vries

    CEO, Hubrecht Organoid Technology
    Robert Vries

    Robert received his PhD in Biochemistry from the Leiden University Medical Center on a molecular study of oncogenic transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of adult stem cells in the group of Prof Hans Clevers at the Hubrecht Institute in The Netherlands.
    In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so-called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology’ (HUB) of which he is currently the CEO.


    Robert received his PhD in Biochemistry from the Leiden University Center on a molecular study of oncogenic transformation. He continued his scientific career as Postdoc at Stanford University (USA). Upon his return to the Netherlands, he joined the group of Hans Clevers at the Hubrecht Institute studying adult stem cells. In the group of Hans Clevers, he was part of the team that developed the ground-breaking technology that allowed the expansion of adult stem cells in vitro. The so-called Organoid Technology became the basis of the company Hubrecht Organoid Technology (HUB) of which he is currently the CEO.
     

    Sakshi Garg

    Lab Head, Merck Group
    Sakshi Garg

    Stefan Przyborski

    Professor of Cell Technology, Durham University
    Stefan Przyborski

    Professor Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, tissue engineering and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 110 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of Reprocell Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. Professor Przyborski is developing new and innovative ways to manage the growth and function of cultured cells. These enabling technologies have multiple applications and will be particularly relevant to bioengineering models of human tissues to advance basic research and drug discovery.

    Stephen J. Fey

    Founder and Chief Research Officer, Celvivo
    Stephen J. Fey

    Suzanne Fitzpatrick

    Senior Science Advisor for Toxicology, FDA
    Suzanne Fitzpatrick

    Dr. Suzanne Fitzpatrick is the Senior Advisor for Toxicology at the US Food and Drug Administration. She is a board-certified toxicologist in the US and in Europe Dr. Fitzpatrick chairs the FDA’s Alternative Methods Work Group that is currently focusing on in vitro Microphysiological Systems. Dr. Fitzpatrick helped develop the FDA DARPA NCATS program on Organs on a Chip and continues to work and give presentations on this evolving area. Dr. Fitzpatrick is an Adjunct Professor at Johns Hopkins University. She received her BA from the University of California at San Diego and her PhD from Georgetown University.

    Thierry Dorval

    Data Scientist Lab Group Leader, Servier
    Thierry Dorval

    Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens.
    In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.
     

    Sponsors

    Official Media Partner

    Supporters

    VENUE

    Online Virtual Event

    Online Virtual Event , Online Virtual Event , United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Sponsors


    CelVivo

    Sponsors
    https://celvivo.com/

    CelVivo provide a 3D Cell Culture technology mimicking in vivo performance.

    The CelVivo system creates an environment which promotes the growth and maintenance of large 3D tissue mimetic structures, whether they are spheroids, organoids, acini and other aggregates.

    Our ambition is to provide cells with conditions which allow them to develop functionality which closely mimics that seen in the intact organism. To achieve this, we have developed a system which obviates the need for scaffolds, gels or any type of additives which might perturb gene expression away from its natural baseline equilibrium. Furthermore, we have very significantly reduced contact with plastics and reduced shear forces.


    Media Partners


    Genetic Engineering News

    Official Media Partner
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    3DMedNet

    Official Media Partner
    https://www.3dmednet.com/

    3DMedNet is an online community providing the latest news, opinions and peer-reviewed journal articles focused on the applications of 3D printing technologies in medicine, including 3D-printed medical devices, surgery, pharmaceuticals, bioprinting, dentistry and the regulatory landscape. Visit 3DMedNet today at: www.3dmednet.com


    Labiotech.eu

    Official Media Partner
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

    Media Partners


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    MedTube

    Supporters
    https://medtube.net/



    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out